IBEC and IRB Barcelona projects awarded funds from the 2017 edition of La Marató de TV3 Blog Post

Yesterday, La Fundació  Marató de TV3 announced the 36 projects awarded funding in the 2017 edition of the telethon, dedicated to infectious diseases. Among them is a project headed by Ernest Giralt, from the Institute for Research in Biomedicine (IRB Barcelona) and Jordi Vila, from the Barcelona Institute for Global Health (ISGlobal), and two projects led by Xavier Fernandez-Busquets and Antonio Juarez from the Institute for Bioengineering of Catalonia (IBEC).

 

Researchers develop a new class of covalent inhibitor for a protein involved in brain diseases Blog Post

An article published in Cell Chemical Biology by scientists at the Institute for Research in Biomedicine (IRB Barcelona) in Barcelona Science Park (PCB) describes a new class of prolyl oligopeptidase (POP) inhibitors. Found mostly in the brain, POP protein has emerged as an “attractive·” therapeutic target for the treatment of several cognitive and neurodegenerative disorders, such as Parkinson’s disease and schizophrenia.The work was done in collaboration with the biotech Iproteos, based in PCB and scientists at the University of Glasgow (Scotland, UK) and the Utrecht Institute for Pharmaceutical Sciences (the Netherlands). The study has also involved the Nuclear Magnetic Resonance Laboratory (LRB) –wich is part of CCiTUB and it’s located in the Cluster building of the Park– and the Barcelona Supercomputing Center (BSC).

 

Mind the Byte wins 2018 Biosuccess Award Blog Post

CataloniaBio & HealthTech awarded the 2018 Biosuccess Award recognising the most important business milestones in biomedicine and health in Catalonia to Anaconda Biomed and Mind the Byte. The ceremony took place during the CataloniaBio & HealthTech Gala Dinner at the Museu Marítim of Barcelona, featuring president of CataloniaBio & HealthTech, Jaume Amat; CEO of ACCIÓ, Joan Romero; director general for Research and Innovation in Health, Albert Barberà; and over 200 entrepreneurs, executives and investors from the sector.

 

Jaume Amat, CEO of Specipig, new president of CataloniaBio & HealthTech Blog Post

CataloniaBio & HealthTech has chosen its first president and board of directors today, after the merger of the CataloniaBio association of companies and the HealthTech Cluster last December, at an extraordinary members’ assembly. The new entity, located at the Barcelona Science Park, represents more than 170 companies, as well as collaborating stakeholders such as hospitals, research centres and universities that are leaders in R&D in biomedicine.

 

Presenting CataloniaBio & HealthTech Blog Post

A new era for the CataloniaBio association of companies and the HealthTech Cluster. Members of the two organisations unanimously passed the motion to merge under the brand CataloniaBio & HealthTech at their respective extraordinary general meetings held in Barcelona yesterday.The headquarters will be located at the Barcelona Science Park. It will promote the convergence of biopharma, MedTech and digital health companies to boost competitiveness and address unmet medical needs 

 

Three innovation projects at IRB Barcelona are granted funding for market development Blog Post

The Catalan’ Government’s Agency for Management and of University and Research Grants (Agencia de Gestió i Ajuts Universitaris i de Recerca (AGAUR)) has awarded around 220,000 euros to three innovation projects underway at the Institute for Research in Biomedicine (IRB Barcelona) at the Barcelona Science Park. These funds have been provided through the 2016 Knowledge Industry grant call, a programme cofunded by European Regional Development Funds (ERDFs) devoted to Catalonia in the period 2014-2020.

 

New research front to tackle Friedreich’s Ataxia Blog Post

The associations of patients and families Babel Family and the Asociación Granadina de la Ataxia de Friedreich (ASOGAF) channel 80,000 euros of their donations (50% from each organisation) into a new 18-month project at the Institute for Research in Biomedicine (IRB Barcelona) located at PCB. The long-term goal of the project is to achieve an injectable frataxin treatment able to reach the brain. Frataxin is the protein that is reduced in those affected by this rare and degenerative disease, which has no cure.